Rani-Logo.jpg
Rani Therapeutics Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study
October 19, 2023 16:05 ET | Rani Therapeutics, LLC
- RaniPill® HC achieved 4/4 successful drug delivery of orally administered Humira® (adalimumab) - - RaniPill® HC has achieved a cumulative >90% success rate across multiple preclinical studies – ...
Rani-Logo.jpg
Rani Therapeutics to Present Abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research
October 12, 2023 16:05 ET | Rani Therapeutics, LLC
SAN JOSE, Calif., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
Rani-Logo.jpg
Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43)
September 18, 2023 08:00 ET | Rani Therapeutics, LLC
- Topline results from this study are expected in early Q1 2024 - Celltrion has a right of first negotiation for RT-111 following positive Phase 1 results SAN JOSE, Calif., Sept. 18, 2023 (GLOBE...
Rani-Logo.jpg
Rani Therapeutics Announces Successful Drug Delivery of High-Capacity Pill in Preclinical Studies
September 07, 2023 16:05 ET | Rani Therapeutics, LLC
- Two preclinical studies of RaniPill® HC achieved 18/20 successful drug delivery of orally administered teriparatide resulting in a cumulative 90% success rate - Rani will continue preclinical...
Rani-Logo.jpg
Rani Therapeutics to Participate in September Investor Conferences
September 06, 2023 08:00 ET | Rani Therapeutics, LLC
SAN JOSE, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
Rani-Logo.jpg
Rani Therapeutics Reports Second Quarter 2023 Financial Results; Provides Corporate Update
August 11, 2023 16:05 ET | Rani Therapeutics, LLC
- Expansion of partnership with Celltrion for development of RT-105 to complement existing partnership for RT-111 - Appointment of Kate McKinley as Chief Business Officer - Presentation of three...
Rani-Logo.jpg
Rani Therapeutics to Participate in August Investor Conferences
August 04, 2023 16:05 ET | Rani Therapeutics, LLC
SAN JOSE, Calif., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
Rani-Logo.jpg
Rani Therapeutics’ Presentation On Oral Delivery of PTH for Osteoporosis Named Presidential Poster Competition Winner at ENDO 2023 Annual Conference
June 21, 2023 08:00 ET | Rani Therapeutics, LLC
SAN JOSE, Calif., June 21, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
Rani-Logo.jpg
Rani Therapeutics Announces Acceptance of Late-Breaking Abstract of Oral Delivery of GLP-1 Agonist at the American Diabetes Association Annual Conference
June 08, 2023 08:00 ET | Rani Therapeutics, LLC
SAN JOSE, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
Rani-Logo.jpg
Rani Therapeutics and Celltrion Expand Partnership to Include Adalimumab Biosimilar for RT-105
June 05, 2023 08:00 ET | Rani Therapeutics, LLC
SAN JOSE, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...